Archive · 25 Jul 2025
Cipla CEO: US Tariffs to Impact Pharma, Not Cripple Industry
The head of Cipla, a big drug company, says that new taxes (tariffs) from the US government might affect the pharmaceutical industry, but it won't be a disaster.
The company recently made more money than last year.
The CEO thinks the taxes on medicines won't be as high as on other products, maybe less than 15%.
They also believe that branded drugs will be more affected than generic drugs.
The company did well in different parts of the world, including the US, Africa, and Europe, which helped them make money.
Cipla's CEO states US tariffs will impact the pharma industry but won't be 'debilitating'.
Cipla reported a 4% revenue increase to ₹6,957 crore and a 10% rise in profit after tax to ₹1,298 crore in Q1 2025.
The CEO believes tariffs on pharmaceuticals will likely be lower than the average 15% on most goods.
The impact of tariffs is expected to be greater on branded drugs compared to generic drugs.
Cipla's Q1 performance included growth in key markets like the US, One Africa, emerging markets, and Europe.
- Who
- Umang Vohra, Cipla's MD and Global CEO, discussed the topic.
- What
- Cipla's CEO discussed the expected impact of US tariffs on the pharmaceutical industry and reported Q1 financial results.
- When
- The statements were made in a post-results media interaction on July 25, 2025, regarding the quarter ending June 30, 2025.
- Where
- The discussion focuses on the US market and global operations.
- Why
- To address concerns about US tariffs and provide an update on the company's financial performance.
Industry Concerns
Cipla's Perspective
Tariff Impact
Industry Concerns
There are concerns in the global pharma industry on the impact of US tariffs.
Cipla's Perspective
Cipla's CEO believes the impact won't be 'debilitating' and is expected to be lower compared to other products.
- Company
- Cipla
- CEO
- Umang Vohra
- Q1 2025 Revenue
- ₹6,957 crore
- Q1 2025 Profit After Tax
- ₹1,298 crore
- Revenue Growth
- 4% (y-o-y)
- Profit Growth
- 10% (y-o-y)
- US Business Revenue
- $226 million